ALUMINUM TRANSFER AS GLUTAMATE COMPLEX THROUGH BLOOD-BRAIN-BARRIER - POSSIBLE IMPLICATION IN DIALYSIS ENCEPHALOPATHY

被引:34
作者
DELONCLE, R [1 ]
GUILLARD, O [1 ]
CLANET, F [1 ]
COURTOIS, P [1 ]
PIRIOU, A [1 ]
机构
[1] FAC MED & PHARM POITIERS,INST MED,F-86034 POITIERS,FRANCE
关键词
Aluminium; electrothermal atomic absorption spec; glutamate complex transfer through blood brain barrier in rats;
D O I
10.1007/BF02990262
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In vitro distribution of aluminium between plasma and erythrocytes has been studied in the presence of variable amounts of sodium l-glutamate. With a red blood cell suspension in isotonic sodium chloride, aluminium remains confined in erythrocytes even when the sodium l-glutamate concentration increases in the medium. Aluminium initially present in plasma penetrates red blood cells when sodium l-glutamate increases in whole blood, showing that this metal is able in vitro to cross the erythrocyte membrane as glutamate complex. In vivo experiments with male Wistar rats prove that aluminium is also able to pass the blood-brain barrier as glutamate complex and deposit in the brain cortex. © 1990 Humana Press Inc.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 26 条
[1]  
ACKRILL P, 1980, LANCET, V2, P692
[2]   DIALYSIS ENCEPHALOPATHY SYNDROME - POSSIBLE ALUMINUM INTOXICATION [J].
ALFREY, AC ;
LEGENDRE, GR ;
KAEHNY, WD .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (04) :184-188
[3]   REVERSAL OF ALUMINUM DIALYSIS ENCEPHALOPATHY AFTER DESFERRIOXAMINE TREATMENT [J].
ARZE, RS ;
PARKINSON, IS ;
CARTLIDGE, NEF ;
BRITTON, P ;
WARD, MK .
LANCET, 1981, 2 (8255) :1116-1116
[4]  
BOURNERIAS F, 1987, NEPHROLOGIE, V8, P27
[5]  
BROWN DJ, 1982, LANCET, V2, P343
[6]  
CASSON IF, 1984, ANN CLIN BIOC 3 0521, P223
[7]  
Crapper DR, 1986, NEUROBIOL AGING, V7, P525
[8]  
DAVIES SC, 1983, LANCET, V2, P181
[9]  
DELAVELLE F, 1977, NOUV PRESSE MED, V6, P941
[10]   GLUTAMATERGIC ABNORMALITIES IN ALZHEIMERS-DISEASE AND A RATIONALE FOR CLINICAL-TRIALS WITH L-GLUTAMATE [J].
DEUTSCH, SI ;
MORIHISA, JM .
CLINICAL NEUROPHARMACOLOGY, 1988, 11 (01) :18-35